Alvotech SA has announced the European launch of Gobivaz®, its biosimilar to Simponi® (golimumab), marking the first marketed biosimilar to Simponi worldwide. The product is being commercialized exclusively in Europe by Advanz Pharma, with launches underway and initial rollout in the United Kingdom supported by a National Health Service $(NHS)$ England tender award. Gobivaz is manufactured at Alvotech's facility in Iceland and will become available across EEA markets as national pricing and reimbursement processes progress.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-008089), on December 23, 2025, and is solely responsible for the information contained therein.